{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:41:07Z","timestamp":1790264467406,"version":"4.1.0"},"reference-count":20,"publisher":"BMJ","issue":"12","funder":[{"DOI":"10.13039\/501100002927","name":"Addenbrooke's Charitable Trust, Cambridge University Hospitals","doi-asserted-by":"publisher","award":["Ref 14\/15 Biii"],"award-info":[{"award-number":["Ref 14\/15 Biii"]}],"id":[{"id":"10.13039\/501100002927","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2019,5,18]]},"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Aim was to assess the feasibility of serum markers to identify individuals at risk for gastro-oesophageal adenocarcinoma to reduce the number of individuals requiring invasive assessment by endoscopy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Blood samples from 56 patients with Barrett\u2019s oesophagus and 202 non-Barrett controls who previously took part in a trial assessing the accuracy of the Cytosponge for Barrett\u2019s oesophagus were assessed for serum pepsinogen (PG) 1 and 2, gastrin-17, trefoil factor 3 (TFF3) and\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      infection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PG1 was pathological (&lt;50\u2009ng\/mL) in 26 patients (10.1%), none of whom had Barrett\u2019s oesophagus (p&lt;0.001). Smoking and drinking had no influence on these results. Pathological PG1 was associated with stomach pain (p=0.029), disruption of sleep (p=0.027) and disruption of diet by symptoms (p=0.019). Serum TFF3 was not associated with any clinical parameter.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Assessment of serum PG1 could be combined with a test for Barrett\u2019s oesophagus to identify additional patients requiring endoscopy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jclinpath-2019-205700","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T08:04:53Z","timestamp":1561449893000},"page":"825-829","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Feasibility of combined screening for upper gastrointestinal adenocarcinoma risk by serology and Cytosponge testing: the SUGAR study"],"prefix":"10.1136","volume":"72","author":[{"given":"Yiwang","family":"Xu","sequence":"first","affiliation":[{"name":"MRC Cancer Unit, Hutchison\/MRC Research Centre, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Miremadi","sequence":"additional","affiliation":[{"name":"Histopathology Department, Cambridge University Hospitals NHS Trust, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Link","sequence":"additional","affiliation":[{"name":"Dept. of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke-University, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Malfertheiner","sequence":"additional","affiliation":[{"name":"Dept. of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke-University, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"MRC Cancer Unit, Hutchison\/MRC Research Centre, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8673-3122","authenticated-orcid":false,"given":"Jan","family":"Bornschein","sequence":"additional","affiliation":[{"name":"MRC Cancer Unit, Hutchison\/MRC Research Centre, University of Cambridge, Cambridge, UK"},{"name":"Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford University Hospitals, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,6,24]]},"reference":[{"key":"2025120618265377000_72.12.825.1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0031-1291491"},{"key":"2025120618265377000_72.12.825.2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-006-0397-0"},{"key":"2025120618265377000_72.12.825.3","first-page":"4129","article-title":"Prevalence of H. pylori infection and atrophic gastritis in a population-based screening with serum biomarker panel (GastroPanel\u00ae) in St. Petersburg","volume":"36","author":"Roman","year":"2016","journal-title":"Anticancer Res"},{"key":"2025120618265377000_72.12.825.4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142080","article-title":"Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis","volume":"10","author":"Huang","year":"2015","journal-title":"PLoS One"},{"key":"2025120618265377000_72.12.825.5","doi-asserted-by":"publisher","DOI":"10.1258\/0969141041732184"},{"key":"2025120618265377000_72.12.825.6","doi-asserted-by":"publisher","DOI":"10.1080\/00365520802273025"},{"key":"2025120618265377000_72.12.825.7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/apt.14248","article-title":"Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis","volume":"46","author":"Zagari","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2025120618265377000_72.12.825.8","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2004.055400"},{"key":"2025120618265377000_72.12.825.9","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2188\/jea.JE20150258","article-title":"Combination of Helicobacter pylori antibody and serum pepsinogen as a good predictive tool of gastric cancer incidence: 20-year prospective data from the Hisayama study","volume":"26","author":"Ikeda","year":"2016","journal-title":"J Epidemiol"},{"key":"2025120618265377000_72.12.825.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001780","article-title":"Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study","volume":"12","author":"Ross-Innes","year":"2015","journal-title":"PLoS Med"},{"key":"2025120618265377000_72.12.825.11","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.180281"},{"key":"2025120618265377000_72.12.825.12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1053\/j.gastro.2011.05.040","article-title":"Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening","volume":"141","author":"Aikou","year":"2011","journal-title":"Gastroenterology"},{"key":"2025120618265377000_72.12.825.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-011-0396-8"},{"key":"2025120618265377000_72.12.825.14","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.114504"},{"key":"2025120618265377000_72.12.825.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.12.012"},{"key":"2025120618265377000_72.12.825.16","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/ajg.2017.55","article-title":"A serological biopsy using five Stomach-Specific circulating biomarkers for gastric cancer risk assessment: a multi-phase study","volume":"112","author":"Tu","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"2025120618265377000_72.12.825.17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1515\/raon-2017-0054","article-title":"Premalignant gastric lesions in patients included in national colorectal cancer screening","volume":"52","author":"Tepes","year":"2018","journal-title":"Radiol Oncol"},{"key":"2025120618265377000_72.12.825.18","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32834d0a0a"},{"key":"2025120618265377000_72.12.825.19","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1326379"},{"key":"2025120618265377000_72.12.825.20","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314600"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2019-205700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T02:27:05Z","timestamp":1765074425000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2019-205700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,24]]},"references-count":20,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,11,20]]},"published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1136\/jclinpath-2019-205700"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2019-205700","relation":{},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,24]]}}}